Dog trials slip Pro Bono's 'bonkers' subQ blood factors into lead
This article was originally published in Scrip
Executive Summary
Pro Bono Bio has unveiled preclinical results that have raised its hopes of bringing to market within four years blood factor products for haemophilia patients that offer improvements over existing products on four fronts: duration of action, mode of administration, evenness of circulating dose and, in the case of Factor VIIa, possibility of prophylactic use for the first time.